Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-18
2006-07-18
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000
Reexamination Certificate
active
07078405
ABSTRACT:
The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula or a salt thereof.Wherein R1denotes a hydrogen atom, a C1-6alkyl group, a C1-6alkoxy group and the like; R2denotes a halogen atom, a cyano group, a nitro group, a C1-10alkyl group, a C2-10alkenyl group, C2-10alkynyl group and the like; R3denotes a C6-14aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may have a substituent; and X, Y and X are independent of each other and each denotes N or CR4(wherein R4denotes a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally halogenated C1-6alkyl group and the like) and, in this case, at least two of X, Y and Z denote CR4.
REFERENCES:
patent: 4596872 (1986-06-01), Davey
patent: 4910199 (1990-03-01), Bourguignon et al.
patent: 5127936 (1992-07-01), Selby
patent: 0068378 (1983-01-01), None
patent: 0353902 (1990-02-01), None
patent: 0611766 (1994-08-01), None
patent: 0611766 (1994-08-01), None
patent: 3-506033 (1991-12-01), None
patent: 10-72449 (1998-03-01), None
patent: 2000-502723 (2000-03-01), None
patent: 2000-109431 (2000-04-01), None
patent: WO90/01030 (1990-02-01), None
patent: WO94/13643 (1994-06-01), None
patent: WO94/13644 (1994-06-01), None
patent: WO94/13661 (1994-06-01), None
patent: WO94/13676 (1994-06-01), None
patent: WO95/10506 (1995-04-01), None
patent: WO95/34563 (1995-12-01), None
patent: WO97/29109 (1997-08-01), None
patent: WO97/29110 (1997-08-01), None
patent: WO98/08847 (1998-03-01), None
patent: WO 98/35967 (1998-08-01), None
patent: WO98/35967 (1998-08-01), None
patent: WO99/40090 (1999-08-01), None
patent: WO 99/40090 (1999-08-01), None
patent: WO-02/06286 (2002-01-01), None
Kehne and De Lombert, “Non-Peptidic CRF1 Receptor Antagonists for the Treatment of Anxiety, Depression and Stress Disorders” Current Drug Targets, vol. 1(5), pp. 467-493 (2002).
Dautzenberg and Hauger, “The CRF peptide family and their receptors: yet more partners discovered” Trends in Pharmacological Sciences, vol. 23(2), pp. 71-77 (Feb. 2002).
Altemus et al., Arch Gen Psychiatry, vol. 51, pp. 794-803, (1994).
Bremner et al., Am. J. Psychiatry, vol. 154, No. 5, pp. 624-629, (1997).
Roy-Byrne et al., Am. J. Psychiatry, vol. 143, No. 7, pp. 896-899, (1986).
Monnikes et al., Brain Research, vol. 574, pp. 70-76, (1992).
Stenzel-Poore et al., J. of Neuroscience, vol. 14, No. 5, pp. 2579-2584, (1994).
Owens et al., J. of Pharma. and Exp. Therapeutics, vol. 258, No. 1, pp. 349-356, (1991).
Kalin et al., Brain Research, vol. 509, pp. 80-84, (1990).
Tazi et al., Regulatory Peptides, vol. 18, pp. 37-42, (1987).
Baldwin et al., Psychopharmacology, vol. 103, pp. 227-232, (1991).
Sirinathsinghji et al., Nature, vol. 305, pp. 232-235, (1983).
Sherman et al., Pharm. Bio. & Behavior, vol. 26, pp. 699-703, (1987).
Lyons et al., Brain Research, vol. 545, pp. 339-342, (1991).
Strijbos et al., Brain Research, vol. 656, pp. 405-408, (1994).
Ehlers et al., Brain Research, vol. 278, pp. 332-336, (1983).
Whitehouse et al., Neurology, vol. 37, pp. 905-909, (1987).
De Souza et al., Brain Research, vol. 437, pp. 355-359, (1987).
Diamant et al., Neuroendocinology, vol. 57-pp. 1071-1081, (1993).
Stenzel-Poore et al., Endocrinology, vol. 130, No. 6, pp. 3378-3386, (1992).
Hotta et al., J. of Clinical Endocrinology and Metabolism, vol. 62, No. 2, pp. 319-324, (1986).
Levine et al., Neuropharmacology, vol. 22, No. 3A, pp. 337-339, (1983).
Krahn et al., Brain Research Bulletin, vol. 17, pp. 285-289, (1986).
Arase et al., Physiology & Behavior, vol. 45, pp. 565-570, (1989).
Plotsky et al., Endocrinology, vol. 130, No. 4, pp. 1931-1941, (1992).
Tache et al., American Journal of Phy., vol. 253, pp. G241-G245, (1987).
Barquist et al., American Journal of Phy., vol. 262, pp. G616-G620 (1992).
Gunion et al., American Journal of Phy., vol. 258, pp. G152-G157, (1990).
Bakke et al., Life Sciences, vol. 45, pp. 907-916, (1989).
Lenz et al., Gastroenterology, vol. 95, pp. 1510-1517, (1988).
Ford et al., Gastroenterology, vol. 109, pp. 1772-1780, (1995).
Lembo et al., Neurogastroenterol. Mot., vol. 8, pp. 9-18, (1996).
Fukudo et al., Gut, vol. 42, pp. 845-849, (1998).
Morimoto et al., J. of Physiology, vol. 460, pp. 221-229, (1993).
Karalis et al., Science, vol. 254, pp. 421-423, (1991).
Crofford et al., J. of Clinical Investigation, Inc., vol. 90, pp. 2555-2564, (1992).
Crofford et al., J. of Immunology, vol. 151, No. 3, pp. 1587-1596, (1993).
Theoharides et al., Endocrinology, vol. 139, No. 1, pp. 403-413, (1998).
Singh et al., J. of Pharmacology and Experimental Therapeutics, vol. 288, No. 3, pp. 1349-1356, (1999).
Scopa et al., Am. J. of Pathology, vol. 145, No. 5, pp. 1159-1167, (1994).
Poliak et al., J. of Immunology, vol. 158, pp. 5751-5756, (1997).
Murakami et al., Endocrine Journal, vol. 44, No. 4, pp. 627-629, (1997).
Singh et al., Neuroscience Letters, vol. 120, pp. 151-154, (1990).
Garrick et al., Regulatory Peptides, vol. 21, pp. 173-181, (1988).
Butler et al., J. of Neuroscience, vol. 10, No. 1, pp. 176-183, (1990).
Owens et al., Pharmacological Reviews, vol. 43, No. 4, pp. 425-473, (1991).
Banki et al., Am. J. Psychiatry, vol. 144, No. 7, pp. 873-877, (1987).
Raadsheer et al., Am. J. Psychiatry, vol. 152, No. 9, pp. 1372-1376, (1995).
Nemeroff et al., Arch. Gen. Psychiatry, vol. 45, pp. 577-579, (1988).
Gold et al., New England J. of Med., vol. 314, No. 21, pp. 1329-1335, (1986).
Chalmers et al., J. of Neuroscience, vol. 15, No. 10, pp. 6340-6350, (1995).
Liaw et al., Endocrinology, vol. 137, No. 1, pp. 72-77, (1996).
Valdenaire et al., Biochimica et Biophysica Acta, vol. 1352, pp. 129-132, (1997).
Vale et al., Recent Progress in Hormone Research, vol. 39, pp. 245-270, (1982).
Vale et al., Science, vol. 213, pp. 1394-1397, (1981).
Rivier et al., Proc. Natl. Acad. Sci., vol. 80, pp. 4851-4855, (1983).
Shibahara et al., EMBO Journal, vol. 2, No. 5, pp. 775-779, (1983).
Sasaki et al., J. of Clinical Endocrinology and Metabolism, vol. 65, No. 1, pp. 176-182, (1987).
Sasaki et al., J. of Clinical Endocrinology and Metabolism, vol. 67, No. 4, pp. 768-773, (1988).
Nicholson et al., Regulatory Peptides, vol. 18, pp. 173-188, (1987).
Petrusz et al., Peptides, vol. 5, Suppl. 1, pp. 71-78, (1984).
Jain et al., Endocrinology, vol. 128, No. 3, pp. 1329-1336, (1991).
Chappell et al., Biological Psychiatry, vol. 39, pp. 776-783, (1996).
Bohmer et al., E. J. of Pharmacology, vol. 182, pp. 405-411, (1990).
Nink et al., Acta Endocrinologica, vol. 127, pp. 200-204, (1992).
Rivier et al., Science, vol. 224, pp. 889-891, (1984).
Menzaghi et al., J. of Pharm. And Experimental Therapeutics, vol. 269, No. 2, pp. 564-572, (1994).
Dunn et al., Brain Research Reviews, vol. 15, pp. 71-100, (1990).
Whitten et al., J. Med. Chem., vol. 39, pp. 4354-4357, (1996).
Behan et al., Nature, vol. 378, p. 284-287, (1995).
Hibi Shigeki
Hoshino Yorihisa
Ino Mitsuhiro
Kikuchi Koichi
Ono Mutsuko
Birch & Stewart Kolasch & Birch, LLP
Eisai Co. Ltd.
Tucker Zachary C.
Wilson James O.
LandOfFree
Imidazo[1,2-b]pyridazine compound does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazo[1,2-b]pyridazine compound, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazo[1,2-b]pyridazine compound will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3533154